Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system.

Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system with many similarities to multiple sclerosis. The main effector cells involved are CD4+ T cells, recognizing encephalitogenic epitopes within the central nervous system, and macrophages, both of which secrete proinflammatory cytokines, such as IFN-gamma and TNF. Studies have shown that immunomodulation of this inflammatory response by anti-inflammatory cytokines (IL-4, IL-10, IFN-beta, and TGF-beta) can reduce clinical severity in EAE. The importance of TNF in EAE has been demonstrated by using soluble TNF-receptor molecules to inhibit EAE. However, the limitation of this type of therapy is the necessity for frequent administration of cytokine proteins due to their short biologic half-life. This study demonstrates that EAE can be inhibited by a single injection of therapeutic cytokine (IL-4, IFN-beta, and TGF-beta) DNA-cationic liposome complex directly into the central nervous system. DNA coding for a novel, dimeric form of human p75 TNF receptor also ameliorated clinical EAE. Local administration of DNA-cationic liposome complex has identified gene targets that may be more efficiently exploited using vectors producing more stable expression for effective treatment of neuroimmunologic disease.

[1]  Y. Chernajovsky.  Systemic gene therapy for arthritis. , 1999, Drugs of today.

[2]  Y. Chernajovsky,et al.  Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis , 1998, Gene Therapy.

[3]  J. Pollard,et al.  Critical Points of Tumor Necrosis Factor Action in Central Nervous System Autoimmune Inflammation Defined by Gene Targeting , 1997, The Journal of experimental medicine.

[4]  V. Tuohy,et al.  Treatment of Experimental Autoimmune Encephalomyelitis with Genetically Modified Memory T Cells , 1997, The Journal of experimental medicine.

[5]  L. Mucke,et al.  Astroglial overproduction of TGF-β1 enhances inflammatory central nervous system disease in transgenic mice , 1997, Journal of Neuroimmunology.

[6]  Y. Chernajovsky,et al.  Pathogenic lymphoid cells engineered to express TGF β1 ameliorate disease in a collagen-induced arthritis model , 1997, Gene Therapy.

[7]  G. Nolan,et al.  Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis , 1997, The Journal of experimental medicine.

[8]  T. Olsson,et al.  The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. , 1996, Journal of immunology.

[9]  M. Wood,et al.  Immune responses to adenovirus vectors in the nervous system , 1996, Trends in Neurosciences.

[10]  J. Wolff.  Gene therapeutics. Methods and applications of direct gene transfer Edited by J. A. Wolff. Published 1994 by Birkhäuser Verlag AG, Basel, Boston. ISBN: 3-7643-3650-1 and 0-8176-3650-1 (hardcover). Price: DM 158.00/£59.00 , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  C. Brosnan,et al.  IL‐10 fails to abrogate experimental autoimmune encephalomyelitis , 1996, Journal of neuroscience research.

[12]  I. Cohen,et al.  Suppressive vaccination with DNA encoding a variable region gene of the T–cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity , 1996, Nature Medicine.

[13]  R. Neve,et al.  Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. , 1996, Cytokine.

[14]  B. Trapp,et al.  Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis , 1996, Journal of Neuroimmunology.

[15]  P. Robbins,et al.  Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. , 1995, Gene therapy.

[16]  C. F. Zhou,et al.  Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. , 1995, Human gene therapy.

[17]  T. Olsson,et al.  Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β , 1995, Journal of Neuroimmunology.

[18]  M. Woodroofe.  Cytokine production in the central nervous system , 1995, Neurology.

[19]  J. Ghrayeb,et al.  Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. , 1995, Immunology.

[20]  R. Seder.  Acquisition of lymphokine-producing phenotype by CD4+ T cells. , 1994, The Journal of allergy and clinical immunology.

[21]  E. Shevach,et al.  Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. , 1994 .

[22]  B. Scallon,et al.  Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins , 1994, European journal of immunology.

[23]  H. Weiner,et al.  Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. , 1994, Cellular immunology.

[24]  E. Shevach,et al.  Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo , 1994, The Journal of experimental medicine.

[25]  B. Fleischer,et al.  Interleukin‐10 prevents experimental allergic encephalomyelitis in rats , 1994, European journal of immunology.

[26]  J. Wolff,et al.  Pharmacological enhancement of in vivo foreign gene expression in muscle. , 1994, Gene Therapy.

[27]  A. Rundell,et al.  Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. , 1993, Human gene therapy.

[28]  T. Kipps,et al.  Systemic immunological effects of cytokine genes injected into skeletal muscle. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Raine,et al.  Chronologic localization of myelin‐reactive cells in the lesions of relapsing EAE , 1993, Neurology.

[30]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Demeneix,et al.  Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. , 1993, Human gene therapy.

[32]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[33]  D. Baker,et al.  Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. , 1993, Cellular immunology.

[34]  M. Feldmann,et al.  Cytokines in autoimmunity. , 1992, Current opinion in immunology.

[35]  K. Mohler,et al.  Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. , 1992, Journal of immunology.

[36]  D. Baker,et al.  Control of immune‐mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone , 1992, Clinical and experimental immunology.

[37]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[38]  J. Abrams,et al.  Strategies of Anti‐Cytokine Monoclonal Antibody Development: Immunoassay of IL‐10 and IL‐5 in Clinical Samples , 1992, Immunological reviews.

[39]  B. Jaffee,et al.  Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium , 1992, Journal of Neuroimmunology.

[40]  G. Repetto,et al.  Direct gene transfer into nonhuman primate myofibers in vivo. , 1992, Human gene therapy.

[41]  B. Beutler,et al.  A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity , 1991, The Journal of experimental medicine.

[42]  L. Leinwand,et al.  Gene transfer into cardiac myocytes in vivo. , 1991, Trends in cardiovascular medicine.

[43]  P. Albert,et al.  Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. , 1991, Journal of immunology.

[44]  R. Clark,et al.  An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis , 1990, The Journal of experimental medicine.

[45]  M. Tsuda,et al.  Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells , 1990, Neuroscience Letters.

[46]  D. Baker,et al.  Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice , 1990, Journal of Neuroimmunology.

[47]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[48]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[49]  K. Selmaj,et al.  Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro , 1988, Annals of neurology.

[50]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[52]  R. Herndon,et al.  MULTICENTRE DOUBLE-BLIND STUDY OF EFFECT OF INTRATHECALLY ADMINISTERED NATURAL HUMAN FIBROBLAST INTERFERON ON EXACERBATIONS OF MULTIPLE SCLEROSIS☆ , 1986, The Lancet.

[53]  D. Baker,et al.  Cytokines in multiple sclerosis , 1996 .

[54]  J. Leiden,et al.  In Vivo Gene Transfer into the Heart , 1994 .

[55]  W. Paul,et al.  Acquisition of lymphokine-producing phenotype by CD4+ T cells. , 1994, Annual review of immunology.

[56]  J. Isner,et al.  Direct myocardial transfection in two animal models. Evaluation of parameters affecting gene expression and percutaneous gene delivery. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[57]  R. Coffman,et al.  Heterogeneity of cytokine secretion patterns and functions of helper T cells. , 1989, Advances in immunology.